Phaseline

Targets › HTT

HTT (Huntingtin): drug programs, companies and trials

6 programs from 5 companies in 8 trials: 5 Phase 1, 2 Phase 2, 1 Phase 3; Neurology; next expected readout Jul 2028.

[Huntingtin]: May play a role in microtubule-mediated transport or vesicle function.; FUNCTION: [Huntingtin, myristoylated N-terminal fragment]: Promotes the formation of autophagic vesicles. (UniProt, P42858)

Open in Phaseline: the race on HTT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisVotoplam
HTT-lowering antisense oligonucleotide
HTTPhase 3Huntington DiseaseJul 2029
RocheTominersen
Huntingtin mRNA antisense inhibitor
HTTPhase 2Huntington Disease–
Alnylam PharmaceuticalsALN-HTT02
HTT-targeting siRNA (RNAi therapeutic targeting huntingtin mRNA)
HTTPhase 1Huntington's DiseaseJul 2028
UniQure BiopharmaAMT-130
rAAV5-miHTT gene therapy - delivers microRNA targeting mutant huntingtin (HTT) mRNA
HTTPhase 1Huntington Disease; Huntington's DiseaseMar 2029
RocheSPK-10001
Gene therapy targeting huntingtin gene
HTTPhase 1Huntington DiseaseJan 2035
ExoRNA BioscienceER2001
antisense oligonucleotide targeting huntingtin mRNA
HTTPhase 1Huntington Disease–

Conditions

Huntington Disease (6) Huntington's Disease (2)

Modalities

other (3), small molecule (3)

Companies

Roche (2) Alnylam Pharmaceuticals (1) UniQure Biopharma (1) Novartis (1) ExoRNA Bioscience (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.